Recent Updates
Recently added Catalysts

Autologous genetically modified AFPᶜ³³²T cells

Phase 1

Hepatocellular Cancer | Gene therapy | Oncology |Adaptimmune Therapeutics PLC Sponsored ADR|Last Updated: Aug 15, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment45
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03132792AFPᶜ³³²T in Advanced HCCPHASE1 ACTIVE NOT_RECRUITING 45 — — May 8, 2017Dec 7, 2025Aug 15, 202521 United States, France +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).
2 years

Determine if treatment with autologous genetically modified T cells, (AFPᶜ³³²T) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments including chemistry, hematology, coagulation, cardiac assessments including ECG, and cardiac Troponin

Secondary Endpoints
Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR)
2 years
Interval between the date of first T cell infusion dose and first documented evidence of CR or PR
2 years
Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause
2 years
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Autologous genetically modified AFPᶜ³³²T cellsEXPERIMENTAL -
Interventions
NameTypeDescription
Autologous genetically modified AFPᶜ³³²T cellsGENETICInfusion of autologous genetically modified AFPᶜ³³²T cells
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites21

Key Inclusion Criteria: 1. Subject is ≥ 18 years and ≤ 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations. 2. Histologically confirmed HCC, not amenable to transplant, resection. Subject...

Countries:United StatesFranceSpainUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT03132792studyFirstPostDate: changed